Literature DB >> 9150193

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.

D Machin, K W Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9150193     DOI： 10.1093/jnci/89.9.659

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

Review 1.  Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.

Authors:  Zhu Yu; Xiaojing Guo; Yicheng Jiang; Lei Teng; Jinwu Luo; Pengfei Wang; Yunsheng Liang; Haitian Zhang
Journal:  Breast Cancer       Date:  2017-07-28       Impact factor: 4.239

2.  Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.

Authors:  Anabel Beatriz Sanchez-Spitman; Dirk-Jan A R Moes; Jesse J Swen; Vincent O Dezentjé; Diether Lambrechts; Patrick Neven; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-29       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.